Vaginal Estrogen: What We Got Wrong, What the Research Actually Shows, and Why the Conversation Is Changing

If there was one topic from PelviCon 2026 that I came home wanting to talk about with nearly every woman I know, it was vaginal estrogen.

Not because it is new.

In fact, local vaginal estrogen has been around for decades.

The surprising part is how much fear and misinformation still surround it—and how much that fear may have prevented women from receiving a treatment that can dramatically improve vaginal, urinary, and sexual health.

At PelviCon, Dr. Rachel Rubin spoke extensively about genitourinary syndrome of menopause (GSM), vaginal hormones, urinary tract infections, sexual health, and the long history of misunderstanding surrounding estrogen therapy.

And this is a conversation that is finally changing.

First: What is vaginal estrogen?

As estrogen levels decline during perimenopause and menopause, the tissues of the vulva, vagina, urethra, and bladder change.

The vaginal tissue becomes thinner and less elastic. Vaginal pH increases. Lubrication decreases. The tissue can become more fragile and irritated.

These changes can contribute to:

• Vaginal dryness

• Burning or irritation

• Pain with penetration

• Pain with sexual activity

• Decreased lubrication

• Changes in sexual function

• Urinary urgency and frequency

• Burning with urination

• Recurrent urinary tract infections (UTIs)

• 
  

Together, these symptoms are commonly referred to as genitourinary syndrome of menopause, or GSM.

And importantly, GSM is not simply a cosmetic or sexual-health issue.

It can affect the urinary system, sexual function, comfort, sleep, exercise, relationships, confidence, and quality of life.

So where does vaginal estrogen fit in?

Unlike systemic hormone therapy—which is designed to affect hormone levels throughout the body—low-dose vaginal estrogen is applied locally to the vaginal tissues.

The goal is to restore estrogen to tissues that have become estrogen-deficient.

And the dose is very small.

This distinction—local versus systemic hormone therapy—is incredibly important.

Yet for years, the FDA labeling on vaginal estrogen carried warnings that made it look as though these medications had the same risks as systemic hormone therapy.

That brings us to one of the most frustrating chapters in the history of women's health.

The Black Box Warning

To understand why women and clinicians became so afraid of estrogen, we need to go back to the early 2000s.

In 2002, the Women's Health Initiative (WHI) published its initial findings from a large randomized trial of menopausal hormone therapy.

The study involved women taking oral conjugated equine estrogen plus medroxyprogesterone acetate—a systemic hormone therapy regimen.

The trial was stopped early because researchers identified increased risks that included breast cancer, cardiovascular events, stroke, and blood clots in the treatment group.

The results received enormous media attention.

Hormone therapy use plummeted.

And the FDA subsequently applied broad boxed-warning language to estrogen-containing products.

Here's the problem:

Not all estrogen therapies are the same.

A systemic oral hormone therapy that raises hormone levels throughout the body is not the same thing as a tiny dose of estrogen applied locally to the vagina.

Different routes.

Different doses.

Different pharmacology.

Different purposes.

And potentially very different risk profiles.

Yet the warning became broadly associated with estrogen products.

That meant a woman prescribed a low-dose vaginal estrogen could open the package and see frightening language about cancer, heart disease, stroke, blood clots, and dementia.

For many women, that was enough to say:

"Nope. I'm not using that."

And many clinicians were understandably hesitant to prescribe it.

The problem with applying systemic data to local treatment

This is one of the most important lessons from the vaginal-estrogen story:

You cannot automatically assume that evidence about one hormone therapy applies equally to every hormone therapy.

Route of administration matters.

Dose matters.

Formulation matters.

Patient age matters.

Timing matters.

And whether a medication produces meaningful systemic hormone exposure matters.

Low-dose vaginal estrogen is designed to work primarily at the tissues where it is applied.

Studies have generally shown minimal systemic absorption with low-dose vaginal estrogen, particularly once the vaginal tissue has been restored.

That does not mean "zero risk for every person in every circumstance."

Medicine rarely works that way.

But it does mean that lumping low-dose vaginal estrogen into the same risk category as systemic hormone therapy is an oversimplification.

And that distinction is finally being recognized at the regulatory level.

The FDA Finally Reconsidered the Label

This change did not happen overnight.

Researchers, clinicians, professional organizations, and patient advocates—including Dr. Rachel Rubin and colleagues—spent years pushing for a more accurate interpretation of the evidence.

The American Urological Association's work on GSM was particularly important.

The AUA's GSM guideline helped establish vaginal estrogen as an evidence-based treatment for GSM and recurrent UTIs, while also addressing the safety concerns that had discouraged both patients and clinicians.

In July 2025, the FDA convened an expert panel on menopause and hormone therapy.

One of the important themes was the need to distinguish systemic hormone therapy from local vaginal estrogen rather than treating every estrogen-containing product as though it carries identical risks.

Then, in November 2025, the FDA announced that it was requesting major changes to menopausal hormone therapy labeling.

And in February 2026, the FDA approved labeling changes for multiple menopausal hormone therapy products, including topical vaginal estrogen.

The outdated boxed-warning language regarding cardiovascular disease, breast cancer, and probable dementia was removed.

That is a major shift.

But I want to be clear about what this means:

Removing a boxed warning does not mean estrogen has magically become a risk-free medication.

It means the FDA recognized that the previous labeling did not adequately reflect the current evidence and the differences among hormone therapies.

That is an important distinction.

So… Is Vaginal Estrogen Actually Safe?

For the vast majority of women with GSM, the evidence says YES!

One of the most important studies comes from the Women's Health Initiative Observational Study.

Researchers followed postmenopausal women who used vaginal estrogen and compared them with women who did not.

Among women with an intact uterus, vaginal-estrogen users did not have significantly higher risks of:

• Breast cancer

• Endometrial cancer

• Stroke

• Blood clots

In fact, several outcomes—including coronary heart disease, fractures, and all-cause mortality—were lower among vaginal-estrogen users.

That does not prove vaginal estrogen caused those women to live longer.

Women who choose or are able to use vaginal estrogen may differ from women who do not in other important ways.

But it provides substantial reassurance that vaginal estrogen is not behaving like the dangerous medication many women have been led to believe it is.

And the evidence has continued to accumulate.

Vaginal Estrogen and Recurrent UTIs

This is where things get especially interesting for pelvic health.

After menopause, declining estrogen changes the vaginal and urinary environment.

The vaginal epithelium becomes thinner, vaginal pH rises, and the protective Lactobacillus-dominant environment can change.

That creates a more favorable environment for urinary pathogens.

And recurrent UTIs are miserable.

They can mean:

• Repeated antibiotics

• Urgent care visits

• Missed work

• Poor sleep

• Pain and burning

• Fear of leaving the house

• Repeated cultures

• Hospitalizations in more serious cases

  
  

Vaginal estrogen can help restore the urogenital environment and has been shown to reduce recurrent UTIs.

A 2026 systematic review and meta-analysis of randomized controlled trials confirmed a protective effect, with an estimated risk around 60% lower in the vaginal-estrogen groups compared with controls.

That's not a small effect.

And this is one reason the treatment is recommended in guidelines for appropriate postmenopausal women with recurrent UTIs.

The Study That Really Got My Attention: Vaginal Estrogen and Mortality

And then there is the study that made me stop and say:

We really need to be talking about this.

A 2026 study using the enormous Epic Cosmos database looked at nearly 1.9 million women with recurrent UTIs.

Researchers compared women who received a prescription for vaginal estrogen after their recurrent UTI diagnosis with those who did not.

The results were striking.

Across multiple age groups, women prescribed vaginal estrogen had lower rates of:

• Sepsis

• Hospitalization

• All-cause mortality

  
  

Mortality was lower in the estrogen group across every age category studied.

Among the oldest women, for example, mortality was approximately 3.9% among vaginal-estrogen recipients compared with 9.6% among those who did not receive it.

That is a remarkable difference.

But here's the important scientific caveat:

This was an observational study.

It shows an association—not proof that vaginal estrogen itself caused the reduction in deaths.

There may be other differences between the groups that researchers cannot completely account for.

So I would not tell a patient, "Vaginal estrogen will make you live longer."

That is not what the study proves.

What I would say is:

The newest evidence is showing that treating GSM and preventing recurrent UTIs may have implications far beyond vaginal comfort—and we are beginning to see data connecting vaginal estrogen use with fewer serious complications and lower mortality.

That deserves our attention.

What About Breast Cancer?

This is where conversations need nuance rather than blanket statements.

The available evidence is reassuring regarding low-dose vaginal estrogen, including observational evidence showing no significant increase in breast cancer incidence or recurrence.

A 2026 review examining vaginal estrogen in breast cancer survivors found minimal systemic absorption and no demonstrated increase in breast cancer incidence, recurrence, or breast-cancer mortality.

But there are still situations where the conversation should involve the patient's oncology team.

For example, a woman with active breast cancer who is taking an aromatase inhibitor has a different clinical situation than a healthy woman with no cancer history.

That does not automatically mean vaginal estrogen is forbidden.

It means the decision deserves individualized, shared decision-making.

This is an important distinction because "vaginal estrogen is safe" should never turn into "every woman should use it without asking questions."

Good medicine is more nuanced than that.

Vaginal Estrogen Isn't Just About UTIs

This may actually be one of my biggest takeaways from PelviCon.

We sometimes think about vaginal estrogen as something prescribed for "vaginal dryness."

That description is far too narrow.

Improving the health of the vaginal and vulvar tissues can affect:

• Lubrication

• Vaginal elasticity

• Pain with penetration

• Sexual comfort

• Arousal

• Urinary urgency

• Urinary frequency

• Burning with urination

• Recurrent UTIs

• Overall quality of life

  
  

And when we consider sexual health, this becomes particularly important.

A woman who has painful, dry, fragile tissue may begin avoiding sex.

She may experience pelvic floor guarding in response to pain.

She may develop fear or anticipation around penetration.

Her sexual function may change.

Her relationship with her body may change.

And then she may end up in pelvic floor physical therapy years later with a problem that began, at least in part, with a hormonal change.

That doesn't mean estrogen is the answer to every pelvic floor problem.

It means we need to recognize when hormonal health is part of the picture.

What About Perimenopause?

Another important conversation is that GSM isn't necessarily something that suddenly appears the day a woman reaches menopause.

Hormonal fluctuations begin during perimenopause, and symptoms can occur during the transition.

Breastfeeding and the postpartum period can also produce a low-estrogen state that causes GSM-like symptoms.

So if a woman is experiencing vaginal dryness, burning, painful sex, urinary symptoms, or recurrent UTIs, it is worth asking:

Could hormones be contributing?

Rather than assuming these symptoms are simply "part of aging."

The Work Isn't Over

Removing the boxed warning was a huge step.

But it is not the finish line.

In fact, this may be where the harder work begins.

Because changing a label does not automatically change clinical practice.

It does not automatically change what a woman was told by her doctor five years ago.

It does not erase the fear created by decades of warnings.

And it does not mean every clinician suddenly feels comfortable prescribing vaginal estrogen.

Dr. Rubin has emphasized this point repeatedly: we need to educate clinicians.

Primary care providers.

Gynecologists.

Urologists.

Oncologists.

Nurse practitioners.

Physician assistants.

And, yes, pelvic health physical therapists.

We also need women to know that urinary urgency, recurrent UTIs, vaginal burning, painful sex, and vaginal dryness are not symptoms they simply have to tolerate because they are getting older.

There are treatments.

And women deserve to know their options.

What I Took Away From PelviCon

My biggest takeaway wasn't simply:

"Vaginal estrogen is safe."

Though true, it was bigger than that.

It was:

We need to stop being afraid of the right treatment because of the wrong data.

The history of vaginal estrogen is a powerful reminder that medicine evolves.

Evidence changes.

Guidelines change.

Labels change.

And sometimes we have to be willing to look at something we've believed for years and ask:

"Is this still true?"

For low-dose vaginal estrogen, the evidence increasingly tells us that the risk-benefit conversation is very different from what many women have been led to believe.

And that matters.

Because GSM is common.

Recurrent UTIs are common.

Painful sex is common.

Urinary symptoms are common.

And suffering in silence should not be the standard of care.

At Trailhead, part of our job is helping women connect the dots between the pelvic floor, bladder, bowel, sexual health, hormones, musculoskeletal system, and nervous system.

Sometimes the missing piece isn't another pelvic floor exercise.

Sometimes it is understanding the hormonal environment the tissues are living in.

And sometimes, the most important thing we can do is help a woman ask her healthcare provider a better question:

"Could vaginal estrogen be appropriate for me?"

This article is intended for education and does not replace individualized medical advice. Vaginal estrogen is a prescription medication. Women with a history of breast or gynecologic cancer, unexplained vaginal bleeding, or other significant medical conditions should discuss their individual risks and benefits with their healthcare provider. If you are currently being treated for breast cancer—particularly if you are taking an aromatase inhibitor—your oncology team should be part of the conversation.

Resources:

• Rachel Rubin's current GSM evidence summary and patient/clinician resources: Rachel Rubin, MD — Genitourinary Syndrome of Menopause. Her page specifically discusses UTI reduction, systemic absorption, breast-cancer safety data, and the history of the boxed-warning issue.

• Rubin & Lee's 2026 AUA discussion of the boxed-warning history and advocacy process: American Urological Association — Transforming GSM Care.

• FDA's February 2026 announcement documenting the approved labeling changes, including topical vaginal estrogen: FDA — Menopausal Hormone Therapy Labeling Changes.

• WHI Observational Study examining breast cancer, cardiovascular events, endometrial cancer and mortality among vaginal-estrogen users: Women's Health Initiative vaginal estrogen study.

• The new 2026 recurrent-UTI/mortality study: nearly 1.9 million women, with lower sepsis, hospitalization and mortality associated with vaginal-estrogen prescribing. This is probably the study you were remembering from PelviCon.

• 2026 systematic review/meta-analysis of randomized trials showing vaginal estrogen reduced recurrent UTI risk, while also appropriately noting the limitations of long-term randomized safety data:

• 2026 review of vaginal estrogen in breast-cancer survivors, finding minimal systemic absorption and no demonstrated increase in recurrence or breast-cancer mortality: